Literature DB >> 14513679

AAV-based gene transfer.

Hildegard Büning1, Stuart A Nicklin, Luca Perabo, Michael Hallek, Andrew H Baker.   

Abstract

Gene therapy remains an attractive form of treatment for a variety of diseases, both inherited and acquired. Recent experience in clinical gene therapy has highlighted important safety issues pertaining to gene delivery in humans. As such, the choice of gene delivery system for individual applications is fundamentally important and must afford efficiency and safety. Adeno-associated viral (AAV) vectors have unique potential among the repertoire of vector systems currently available. Here, we highlight recent developments to suggest that AAV vectors will play a key role in the future deployment of genetic medicine in humans.

Entities:  

Mesh：

Year:  2003        PMID： 14513679

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  11 in total

Review 1.  A realistic chance for gene therapy in the near future.

Authors:  Stefan Worgall
Journal:  Pediatr Nephrol       Date:  2004-11-10       Impact factor: 3.714

2.  Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism.

Authors:  Luca Perabo; Daniela Goldnau; Kathryn White; Jan Endell; Jorge Boucas; Sibille Humme; Lorraine M Work; Hanna Janicki; Michael Hallek; Andrew H Baker; Hildegard Büning
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Protection of mice from lethal Escherichia coli infection by chimeric human bactericidal/permeability-increasing protein and immunoglobulin G1 Fc gene delivery.

Authors:  Jindong Chen; Chengyao Li; Yuanzhi Guan; Qingli Kong; Chen Li; Xianghua Guo; Qinghua Chen; Xuefang Jing; Zhe Lv; Yunqing An
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

Review 4.  New strategies for cardiovascular gene therapy: regulatable pre-emptive expression of pro-angiogenic and antioxidant genes.

Authors:  Jozef Dulak; Anna Zagorska; Barbara Wegiel; Agnieszka Loboda; Alicja Jozkowicz
Journal:  Cell Biochem Biophys       Date:  2006       Impact factor: 2.194

Review 5.  New vectors and strategies for cardiovascular gene therapy.

Authors:  Agnieszka Jazwa; Alicja Jozkowicz; Jozef Dulak
Journal:  Curr Gene Ther       Date:  2007-02       Impact factor: 4.391

6.  AAV-mediated gene targeting is significantly enhanced by transient inhibition of nonhomologous end joining or the proteasome in vivo.

Authors:  Nicole K Paulk; Laura Marquez Loza; Milton J Finegold; Markus Grompe
Journal:  Hum Gene Ther       Date:  2012-06-25       Impact factor: 5.695

7.  Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy.

Authors:  Megumi Adachi; Michel Barrot; Anita E Autry; David Theobald; Lisa M Monteggia
Journal:  Biol Psychiatry       Date:  2007-11-05       Impact factor: 13.382

Review 8.  Adeno-associated virus: from defective virus to effective vector.

Authors:  Manuel A F V Gonçalves
Journal:  Virol J       Date:  2005-05-06       Impact factor: 4.099

9.  Effect of vascular endothelial growth factor gene therapy on post-traumatic peripheral nerve regeneration and denervation-related muscle atrophy.

Authors:  S Moimas; F Novati; G Ronchi; S Zacchigna; F Fregnan; L Zentilin; G Papa; M Giacca; S Geuna; I Perroteau; Z M Arnež; S Raimondo
Journal:  Gene Ther       Date:  2013-05-30       Impact factor: 5.250

10.  Adeno-associated viral serotypes produce differing titers and differentially transduce neurons within the rat basal and lateral amygdala.

Authors:  Roopashri Holehonnur; Jonathan A Luong; Dushyant Chaturvedi; Anthony Ho; Srihari K Lella; Matthew P Hosek; Jonathan E Ploski
Journal:  BMC Neurosci       Date:  2014-02-18       Impact factor: 3.288
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.